Lactobacillus reuteri protectis DSM 17938 at high doses versus placebo in children with acute gastroenteritis in a Pediatric Emergency Department
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Ricardo Iramain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Emergency Department, Hospital de Clínicas, Faculty of Medical Sciences, National University of Asunción, San Lorenzo, Paraguay. Hauptthemen laut MEDLINE: Limosilactobacillus reuteri, Gastroenteritis, Probiotics, Diarrhea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Acute gastroenteritis (AGE) is a frequent cause of infant morbidity and mortality. There are many adjuvants therapeutic strategies for treatment, including probiotics, however, their efficacy is still debated. To assess the efficacy of the strain Lactobacillus reuteri DSM 17938 adjunct to oral rehydration therapy (ORT) in the treatment of children with AGE.
Methods
Randomized, controlled, double‐blind, clinical trial conducted in a pediatric emergency department (PED) from October 2021 to January 2023. Children between 1 and 60 months of age with AGE, absence of or mild to moderate dehydration, were included. Clinical and management characteristics were recorded.
Results
Sixty‐two patients in L. reuteri (group 1) and seventy patients in the placebo group (group 2) were included. Group 1 had less duration of diarrhea (2.77 ± 0.6 vs. 3.10 ± 1.1 days; p = 0.036). The mean frequencies of watery diarrhea in group 1 versus 2 on Days 2, 3, 4, and 5 were less in group 1. Watery diarrhea persisted in 58.6% in group 2 and in 19.4% of group 1 at 5 days of treatment.
Conclusions
This study shows that L. reuteri DSM 17938 is effective in decreasing frequency and consistency of stools; and is safe at high doses in patients from 1 month to 5 years of age, in emergency management. It is a low‐risk and easy‐to‐administer intervention, which could reduce complications associated with losses due to AGE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Emergency Department, Hospital de Clínicas, Faculty of Medical Sciences, National University of Asunción, San Lorenzo, Paraguay.
ORCID-Profile: Ricardo Iramain, Alfredo Jara, Laura Cardozo, Rocío Morinigo
Förderung
- None
Zitieren
APA
Iramain, R., Jara, A., Ortiz, J., Cardozo, L., & Morinigo, R. (2025). Lactobacillus reuteri protectis DSM 17938 at high doses versus placebo in children with acute gastroenteritis in a Pediatric Emergency Department. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70026
Vancouver
Iramain R, Jara A, Ortiz J, Cardozo L, Morinigo R. Lactobacillus reuteri protectis DSM 17938 at high doses versus placebo in children with acute gastroenteritis in a Pediatric Emergency Department. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70026
BibTeX
@article{Iramain2025,
author = {Iramain, Ricardo and Jara, Alfredo and Ortiz, Jorge and Cardozo, Laura and Morinigo, Rocío},
title = {Lactobacillus reuteri protectis DSM 17938 at high doses versus placebo in children with acute gastroenteritis in a Pediatric Emergency Department},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70026}
}
EUVIMED